Jennison Associates’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-519,953
| Closed | -$73M | – | 618 |
|
|
2025
Q3 | $73M | Sell |
519,953
-50,915
| -9% | -$6.9M | 0.04% | 168 |
|
|
2025
Q2 | $71.8M | Sell |
570,868
-233,598
| -29% | -$26.8M | 0.04% | 168 |
|
|
2025
Q1 | $89M | Sell |
804,466
-16,228
| -2% | -$2.06M | 0.06% | 143 |
|
|
2024
Q4 | $112M | Buy |
820,694
+485,894
| +145% | +$60.1M | 0.07% | 132 |
|
|
2024
Q3 | $38.6M | Sell |
334,800
-164,523
| -33% | -$22.6M | 0.02% | 261 |
|
|
2024
Q2 | $68.7M | Buy |
499,323
+153,877
| +45% | +$21.1M | 0.04% | 166 |
|
|
2024
Q1 | $47.6M | Sell |
345,446
-106,016
| -23% | -$14.5M | 0.03% | 223 |
|
|
2023
Q4 | $59.5M | Buy |
451,462
+41,987
| +10% | +$4.83M | 0.04% | 174 |
|
|
2023
Q3 | $46.1M | Buy |
409,475
+189,345
| +86% | +$19.9M | 0.04% | 185 |
|
|
2023
Q2 | $20.8M | Sell |
220,130
-6,250
| -3% | -$611K | 0.02% | 312 |
|
|
2023
Q1 | $22.9M | Buy |
226,380
+6,993
| +3% | +$728K | 0.02% | 312 |
|
|
2022
Q4 | $26.2M | Buy |
219,387
+78,057
| +55% | +$9.14M | 0.03% | 285 |
|
|
2022
Q3 | $15M | Buy |
141,330
+2,214
| +2% | +$225K | 0.01% | 355 |
|
|
2022
Q2 | $13.6M | Buy |
+139,116
| New | +$12.8M | 0.01% | 362 |
|
|
2020
Q3 | – | Sell |
-341,858
| Closed | -$41.7M | – | 669 |
|
|
2020
Q2 | $41.7M | Sell |
341,858
-40,302
| -11% | -$4.45M | 0.04% | 196 |
|
|
2020
Q1 | $33.1M | Buy |
382,160
+134,632
| +54% | +$13.2M | 0.04% | 189 |
|
|
2019
Q4 | $26.6M | Buy |
247,528
+14,547
| +6% | +$1.52M | 0.03% | 273 |
|
|
2019
Q3 | $21M | Sell |
232,981
-258,905
| -53% | -$24.2M | 0.02% | 307 |
|
|
2019
Q2 | $41.5M | Buy |
491,886
+82,908
| +20% | +$6.81M | 0.04% | 237 |
|
|
2019
Q1 | $36M | Sell |
408,978
-17,256
| -4% | -$1.44M | 0.04% | 274 |
|
|
2018
Q4 | $30.4M | Buy |
426,234
+22,266
| +6% | +$2.13M | 0.03% | 284 |
|
|
2018
Q3 | $49.7M | Buy |
403,968
+3,556
| +0.9% | +$403K | 0.05% | 254 |
|
|
2018
Q2 | $39.3M | Buy |
400,412
+7,877
| +2% | +$705K | 0.04% | 298 |
|
|
2018
Q1 | $32.6M | Buy |
392,535
+67,112
| +21% | +$5.67M | 0.03% | 324 |
|
|
2017
Q4 | $25.3M | Buy |
325,423
+4,278
| +1% | +$292K | 0.02% | 365 |
|
|
2017
Q3 | $19.7M | Sell |
321,145
-971
| -0.3% | -$51.2K | 0.02% | 406 |
|
|
2017
Q2 | $14.8M | Sell |
322,116
-328,256
| -50% | -$15.9M | 0.02% | 444 |
|
|
2017
Q1 | $28.2M | Buy |
650,372
+280,963
| +76% | +$12M | 0.03% | 373 |
|
|
2016
Q4 | $14.3M | Buy |
369,409
+1,253
| +0.3% | +$56.7K | 0.02% | 452 |
|
|
2016
Q3 | $18.6M | Sell |
368,156
-1,656
| -0.4% | -$82.5K | 0.02% | 425 |
|
|
2016
Q2 | $16.8M | Sell |
369,812
-428
| -0.1% | -$19.7K | 0.02% | 419 |
|
|
2016
Q1 | $14.6M | Sell |
370,240
-124,367
| -25% | -$4.94M | 0.02% | 434 |
|
|
2015
Q4 | $28M | Sell |
494,607
-376,812
| -43% | -$19.2M | 0.03% | 378 |
|
|
2015
Q3 | $34.7M | Sell |
871,419
-4,312
| -0.5% | -$208K | 0.04% | 362 |
|
|
2015
Q2 | $41.8M | Buy |
875,731
+6,063
| +0.7% | +$257K | 0.04% | 370 |
|
|
2015
Q1 | $34.5M | Sell |
869,668
-12,487
| -1% | -$447K | 0.03% | 387 |
|
|
2014
Q4 | $19.7M | Buy |
+882,155
| New | +$16.7M | 0.02% | 439 |
|
|
2013
Q4 | – | Sell |
-1,642,465
| Closed | -$18.6M | – | 723 |
|
|
2013
Q3 | $18.6M | Sell |
1,642,465
-10,181
| -0.6% | -$140K | 0.02% | 444 |
|
|
2013
Q2 | $22.1M | Buy |
+1,652,646
| New | +$20.3M | 0.02% | 419 |
|
Other funds holding NBIX
Jennison Associates's NBIX Position: Q4 2025 in Review
Jennison Associates sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 519,953 shares — an estimated $73M sold.
Jennison Associates first reported a position in NBIX in Q2 2013 and held it in 39 quarters. The position peaked at $112M in Q4 2024. 732 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.
- Jennison Associates reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
- Jennison Associates sold 519,953 Neurocrine Biosciences shares in Q4 2025, an estimated $73M.
- Jennison Associates first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 39 quarters.
- Jennison Associates's Neurocrine Biosciences position peaked at $112M in Q4 2024.
- 732 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.
Based on Jennison Associates's 13F filing for Q4 2025, filed 30 Jan 2026.